Skip to main content
Apollomics Inc. logo

Apollomics Inc. — Investor Relations & Filings

Ticker · APLM ISIN · KYG0411D1236 US Manufacturing
Open in API
Filings indexed 136 across all filing types
Latest filing 2026-04-27 Regulatory Filings
Country US United States of America
Listing US APLM

About Apollomics Inc.

https://www.apollomicsinc.com

Apollomics Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapies. The company's approach centers on creating treatments, particularly combination therapies, that can be integrated with other options to inhibit cancer. These therapies are designed to harness the body's immune system and target specific molecular pathways. Apollomics utilizes a science-driven methodology, including in-house research and development and rigorous clinical trials based on sound mechanistic rationale, with the goal of transforming the treatment landscape for patients with difficult-to-treat cancers.

Recent filings

Filing Released Lang Actions
6-K - Apollomics Inc. (0001944885) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted pursuant to SEC rules. It includes a press release titled 'Apollomics Reports Full Year 2025 Financial Results and Highlights Clinical Updates and Business Progress.' The document explicitly states that the press release is being furnished and shall not be deemed 'filed' for purposes of certain sections of the Exchange Act, indicating this is an announcement rather than the full financial report itself. The document length is only 2071 characters, which is quite short and consistent with a regulatory announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes such press release announcements filed on Form 6-K.
2026-04-27 English
20-F - Apollomics Inc. (0001944885) (Filer)
Annual Report FY 2025
2026-04-24 English
6-K - Apollomics Inc. (0001944885) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Apollomics Inc., reporting a material definitive agreement and related party transaction involving a convertible promissory note. It is a regulatory filing that provides specific information about a financing transaction and related party approval but does not contain comprehensive financial statements or detailed financial analysis. The document length is 3881 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. The content focuses on disclosure of a financing event and related party transaction, typical of a Regulatory Filing (RNS) rather than a Capital/Financing Update (CAP) because it is a formal SEC filing (Form 6-K) reporting the event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-01 English
3 - Apollomics Inc. (0001944885) (Issuer)
Director's Dealing
2026-03-19 English
3 - Apollomics Inc. (0001944885) (Issuer)
Director's Dealing
2026-03-18 English
3 - Apollomics Inc. (0001944885) (Issuer)
Director's Dealing
2026-03-18 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.